Research perspectives: The 2013 AAOS/ORS research symposium on Bone Quality and Fracture Prevention

Journal of Orthopaedic Research

Volumn 32, Issue 7, 2014, Pages 855-864

  Donnelly, Eve ^a,b   Lane, Joseph M ^b   Boskey, Adele L ^b  

^a Cornell University   (United States)

^b HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

bone quality; fracture prevention; fragility fracture; workshop

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; DENOSUMAB; ESTROGEN; GLUCOCORTICOID; PARATHYROID HORMONE[1-34]; PREDNISONE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

AGING; ALBERS SCHOENBERG DISEASE; BONE DENSITY; BONE DISEASE; BONE FRAGILITY; BONE MINERAL; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG APPROVAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR FRACTURE; FINITE ELEMENT ANALYSIS; FOOD AND DRUG ADMINISTRATION; FRACTURE; FRACTURE FIXATION; FRAGILITY FRACTURE; GAIT; GENETIC VARIABILITY; GENOME; HERITABILITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HIP FRACTURE; HUMAN; HYPOPHOSPHATEMIC RICKETS; LOADING TEST; MEDICAL RESEARCH; META ANALYSIS (TOPIC); NON INVASIVE PROCEDURE; NONHUMAN; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHENOTYPE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RAMAN SPECTROMETRY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK; RISK REDUCTION; UNITED STATES;

BONE QUALITY; FRACTURE PREVENTION; FRAGILITY FRACTURE; WORKSHOP;

ANIMALS; BIOMEDICAL RESEARCH; BONE AND BONES; FRACTURES, BONE; HUMANS; ORTHOPEDICS; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84900005923     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22626     Document Type: Review

References (58)

1. Bouxsein ML, Seeman E,. 2009. Quantifying the material and structural determinants of bone strength. Best Pract Res Clin Rheumatol 23: 741-753.
2. McDonnell P, McHugh PE, O'Mahoney D,. 2007. Vertebral osteoporosis and trabecular bone quality. Ann Biomed Eng 35: 170-189.
3. Cooper C, Cole ZA, Holroyd CR, et al. IOF CSA Working Group on Fracture Epidemiology. 2011. Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 22: 1277-1288.
4. Tang SY, Zeenath U, Vashishth D,. 2007. Effects of non-enzymatic glycation on cancellous bone fragility. Bone 40: 1144-1151.
5. Donnelly E, Meredith DS, Nguyen JT, et al. 2012. Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res 27: 672-678.
6. Jepsen KJ,. 2011. Functional interactions among morphologic and tissue quality traits define bone quality. Clin Orthop Relat Res 469: 2150-2159.
7. van der Meulen MC, Jepsen KJ, Mikic̈ B,. 2001. Understanding bone strength: size isn't everything. Bone 29: 101-104.
8. Schlecht SH, Jepsen KJ,. 2013. Functional integration of skeletal traits: an intraskeletal assessment of bone size, mineralization, and volume covariance. Bone 56: 127-138.
9. Allen MR, Reinwald S, Burr DB,. 2008. Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment. Calcif Tissue Int 82: 354-360.
10. Allen MR, Erickson AM, Wang X, et al. 2010. Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone. Calcif Tissue Int 86: 67-71.
11. Viguet-Carrin S, Roux JP, Arlot ME, et al. 2006. Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. Bone 39: 1073-1079.
12. Boskey AL, Robery PG,. 2013. The regulatory role of matrix proteins in mineralizaiton of bone. In:, Marcus R, Feldman D, Dempster DW, Luckey M, Cauley JA, editors. Osteoporosis, Fourth Edition, volume 1. Waltham MA: Elsevier, Academic Press. Chapter 11: p 235-258.
13. Feng JQ, Ward LM, Liu S, et al. 2006. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38: 1310-1315.
14. Ameye L, Young MF,. 2002. Mice deficient in small leucine-rich proteoglycans: novel in vivo models for osteoporosis, osteoarthritis, Ehlers-Danlos syndrome, muscular dystrophy, and corneal diseases. Glycobiology 12: 107R-116R.
15. Mashiba T, Turner CH, Hirano T, et al. 2001. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28: 524-531.
16. Chapurlat RD, Arlot M, Burt-Pichat B, et al. 2007. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 22: 1502-1509.
17. Stepan JJ, Burr DB, Pavo I, et al. 2007. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 41: 378-385.
18. Allen MR, Burr DB,. 2011. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know. Bone 49: 56-65.
19. Krug R, Carballido-Gamio J, Banerjee S, et al. 2008. In vivo ultra-high-field magnetic resonance imaging of trabecular bone microaritecture at 7 T. J Magn Reson Imaging 27: 854-859.
20. Liu XS, Zhang XH, Sekhon KK, et al. 2010. High-resolution peripheral quantitative computed tomography can assess microstructural and mechanical properties of human distal tibial bone. J Bone Miner Res 25: 746-756.
21. Hong J, Cabe GD, Tedrow JR, et al. 2004. Failure of trabecular bone with simulated lytic defects can be predicted non-invasively by structural analysis. J Orthop Res 22: 479-486.
22. Wang X, Sanyal A, Cawthon PM,. et al. 2012. Prediction of new clinical vertebral fractures in elderly men using finite element analysis of CT scans. J Bone Miner Res 27: 808-816.
23. Marini JC, Blissett AR,. 2013. New genes in bone development: what's new in osteogenesis imperfecta. J Clin Endocrinol Metab 98: 3095-3103.
24. Carriero A, Zimmermann EA, Paluszny A, et al. 2014. How tough is brittle bone? investigating osteogenesis imperfecta in mouse bone. J Bone Miner Res doi: 10.1002/jbmr.2172 [Epub ahead of print]
25. Valdar W, Flint J, Mott R,. 2006. Simulating the collaborative cross: power of quantitative trait loci detection and mapping resolution in large sets of recombinant inbred strains of mice. Genetics 172: 1783-1797.
26. Rossini M, Gatti D, Adami S,. 2013. Involvement of WNT/β-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int 93: 121-132.
27. Virk MS, Alaee F, Tang H, et al. 2013. Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model. J Bone Joint Surg Am 95: 694-701.
28. Baron R, Kneissel M,. 2013. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med 19: 179-192.
29. Kramer I, Halleux C, Keller H, et al. 2010. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol 30: 3071-3085.
30. Chakkalakal SA, Zhang D, Culbert AL, et al. 2012. An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva. J Bone Miner Res 27: 1746-1756.
31. Shore EM, Kaplan FS,. 2010. Inherited human diseases of heterotopic bone formation. Nat Rev Rheumatol 6: 518-527.
32. Cole JH, van der Meulen MCH,. 2011. Whole bone mechanics and bone quality. Clin Orthop Relat Res 469: 2139-2149.
33. Jepsen KJ, Schlecht SH,. 2014. Individuals with type II diabetes show increased fracture incidence despite having normal BMD. J Bone Miner Res 28: 784-786.
34. Herman BC, Cardoso L, Majeska RJ, et al. 2010. Activation of bone remodeling after fatigue: differential response to linear microcracks and diffuse damage. Bone 47: 766-772.
35. Berenson JR, Lichtenstein A, Porter L, et al. 1996. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 334: 488-493.
36. Tsai SH, Huang PH, Chang WC, et al. 2012. Zoledronate inhibits ischemia-induced neovascularization by impairing the mobilization and function of endothelial progenitor cells. PLoS ONE 7: e41065.
37. Lehner B, Bauer J, Rödel F, et al. 2004. Radiation-induced impairment of osseous healing with vascularized bone transfer: experimental model using a pedicled tibia flap in rat. Int J Oral Maxillofac Surg 33: 486-492.
38. Gong B, Oest ME, Mann KA, et al. 2013. Raman spectroscopydemonstrates prolonged alteration of bone chemical composition following extremity localized irradiation. Bone 57: 252-258.
39. Sabbagh Y, Graciolli FG, O'Brien S, et al. 2012. Repression of osteocytes Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res 27: 1757-1772.
40. Easley SK, Jekir MG, Burghardt AJ, et al. 2010. Contribution of the intra-specimen variations in tissue mineralization to PTH- and raloxifene-induced changes in stiffness of rat vertebrae. Bone 46: 1162-1169.
41. Lane NE, Yao W, Balooch M, et al. 2006. Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J Bone Miner Res 21: 466-476.
42. Allen MR, Iwata K, Phipps R, et al. 2006. Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment of risedronate or alendronate. Bone 39: 872-879.
43. Allen MR, Hogan HA, Hobbs WA, et al. 2007. Raloxifene enhances material-level mechanical properties of femoral cortical and trabecular bone. Endocrinology 148: 3908-3913.
44. Allen MR, Iwata K, Sato M, et al. 2006. Raloxifene enhances vertebral mechanical properties independent of density. Bone 39: 1130-1135.
45. Silman AJ,. 1995. The patient with fracture: the risk of subsequent fractures. Am J Med 98: 12S-16S.
46. Cramer JA, Gold DT, Silverman SL, et al. 2007. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 18: 1023-1031.
47. Shane E, Burr D, Abrahamsen B, et al. 2014. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American society for bone and mineral research. J Bone Miner Res 29: 1-23.
48. Kanis JA, Johnell O, Oden A, et al. 2008. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19: 385-397.
49. Mitchell PJ,. 2013. Best practices in secondary fracture prevention: fracture liaison services. Curr Osteoporos Rep 11: 52-60.
50. Peichl P, Holzer LA, Maier R, et al. 2011. Parathyroid hormone 1-84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. J Bone Joint Surg Am 93: 1583-1587.
51. Nakamura T, Sugimoto T, Nakano T, et al. 2012. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 97: 3097-3106.
52. Niehrs C,. 2006. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 25: 7469-7481.
53. Bhandari M, Tornetta P III, Hanson B, et al. 2009. Optimal internal fixation for femoral neck fractures: multiple screws or sliding hip screws ? J Orthop Trauma 23: 403-407.
54. Gedmintas L, Solomon DH, Kim SC,. 2013. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 28: 1729-1737.
55. Diab DL, Watts NB,. 2012. Bisphosphonates in the treatment of osteoporosis. Endocrinol Metab Clin North Am 41: 487-506.
56. Donnelly E,. 2011. Methods for assessing bone quality. Clin Orthop Relat Res 469: 2128-2138.
57. Gennari L, Bilezikian JP,. 2009. Glucocorticoid-induced osteoporosis: hope on the HORIZON. Lancet 373: 1225-1226.
58. Donnelly E, Saleh A, Unnanuntana A, Lane JM,. 2012. Atypical femoral fractures: epidemiology, etiology, and patient management. Curr Opin Support Palliat Care 6: 348-354.